MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Molecular Insight Pharmaceuticals, Inc
Organization & Developments: Molecular Insights
Parents
Molecular Insight Pharmaceuticals, Inc
Children
2010: Molecular Insight Announces Ch. 11, Restructuring (2010)
2010: Molecular Insight has five clinical-stage candidates in development. (2010)
Azedra, which has Orphan Drug status and a Fast Track designation by the FDA
Biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification a
Discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in molecular medicine.
Onalta, which has Orphan Drug status
Radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology
Zemiva:clinical-stage molecular imaging pharmaceutical product candidate
Jumps
*Key People: Molecular Insights
Finance & Acquisitions: Molecular Insights